These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3047198)
21. Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. Wilber DJ; Olshansky B; Moran JF; Scanlon PJ Circulation; 1990 Aug; 82(2):350-8. PubMed ID: 2372886 [TBL] [Abstract][Full Text] [Related]
22. Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. Rae AP; Kay HR; Horowitz LN; Spielman SR; Greenspan AM J Am Coll Cardiol; 1988 Jul; 12(1):131-9. PubMed ID: 3379198 [TBL] [Abstract][Full Text] [Related]
23. A dual electrophysiologic test for atrial antireentry and ventricular antifibrillatory studies. Effects of bethanidine, procainamide, and WY-48986. Wu KM; Hunter TL; Proakis AG J Pharmacol Methods; 1990 Apr; 23(2):87-95. PubMed ID: 2332983 [TBL] [Abstract][Full Text] [Related]
24. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. Mason JW N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150 [TBL] [Abstract][Full Text] [Related]
25. The role of combination therapy with mexiletine and procainamide in patients with inducible sustained ventricular tachycardia refractory to intravenous procainamide. Widerhorn J; Sager PT; Rahimtoola SH; Bhandari AK Pacing Clin Electrophysiol; 1991 Mar; 14(3):420-6. PubMed ID: 1708872 [TBL] [Abstract][Full Text] [Related]
26. Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias. Hohnloser SH; Raeder EA; Podrid PJ; Graboys TB; Lown B Am Heart J; 1987 Jul; 114(1 Pt 1):1-7. PubMed ID: 3604854 [TBL] [Abstract][Full Text] [Related]
27. [Are anti-arrhythmia agents superior to a beta blocker in treating life-threatening ventricular arrhythmias? Preliminary results of a controlled study]. Steinbeck G; Andresen D; von Leitner ER Z Kardiol; 1986; 75 Suppl 5():47-55. PubMed ID: 2435071 [TBL] [Abstract][Full Text] [Related]
28. Prospective comparison of intravenous quinidine and intravenous procainamide in patients undergoing electrophysiologic testing. Holzberger PT; Greenberg ML; Paicopolis MC; Ozahowski TP; Ho PC; O'Connor GT Am Heart J; 1998 Jul; 136(1):49-56. PubMed ID: 9665218 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of encainide for malignant ventricular arrhythmias. Tordjman T; Podrid PJ; Raeder E; Lown B Am J Cardiol; 1986 Aug; 58(5):87C-95C. PubMed ID: 3092625 [TBL] [Abstract][Full Text] [Related]
30. Promotion of ventricular tachycardia induction by procainamide in dogs with inducible ventricular fibrillation late after myocardial infarction. Hunt GB; Ross DL Pacing Clin Electrophysiol; 1990 Jul; 13(7):882-9. PubMed ID: 1695745 [TBL] [Abstract][Full Text] [Related]
31. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease. Weintraub AR; Manolis AS; Estes NA Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017 [TBL] [Abstract][Full Text] [Related]
32. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. Roden DM; Lee JT; Woosley RL; Echt DS Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262 [TBL] [Abstract][Full Text] [Related]
33. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia. Pratt CM; Francis MJ; Seals AA; Zoghbi W; Young JB Am J Cardiol; 1990 Jul; 66(1):68-74. PubMed ID: 2193498 [TBL] [Abstract][Full Text] [Related]
34. Electrophysiologic and antiarrhythmic effects of magnesium in patients with inducible ventricular tachyarrhythmia. Hilton TC; Fredman C; Holt DJ; Bjerregaard P; Ira GH; Janosik DL Clin Cardiol; 1992 Mar; 15(3):176-80. PubMed ID: 1551265 [TBL] [Abstract][Full Text] [Related]
35. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction. Kus T; Costi P; Dubuc M; Shenasa M Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538 [TBL] [Abstract][Full Text] [Related]
36. Usefulness of sotalol for life-threatening ventricular arrhythmias. Roden DM Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727 [TBL] [Abstract][Full Text] [Related]
37. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926 [TBL] [Abstract][Full Text] [Related]
38. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation. Stanton MS; Prystowsky EN; Fineberg NS; Miles WM; Zipes DP; Heger JJ J Am Coll Cardiol; 1989 Jul; 14(1):209-15; discussion 216-7. PubMed ID: 2738263 [TBL] [Abstract][Full Text] [Related]
39. Electrophysiologic drug testing in patients with malignant ventricular arrhythmias: importance of stimulation at more than one ventricular site. Morady F; Hess D; Scheinman MM Am J Cardiol; 1982 Nov; 50(5):1055-60. PubMed ID: 7137032 [TBL] [Abstract][Full Text] [Related]
40. Drug response at electropharmacologic study in patients with ventricular tachyarrhythmias: the importance of ventricular refractoriness. Gillis AM; Wyse DG; Duff HJ; Mitchell LB J Am Coll Cardiol; 1991 Mar; 17(4):914-20. PubMed ID: 1999629 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]